SGO

Lancaster Resources Acquires Piney Lake Gold Property

Retrieved on: 
Wednesday, April 10, 2024
Copper, SGO, Quartz, Geology, News, Mineral, LCR, Pikoo, Gold, Acquisition, Peng, National instrument, Mining, Operation, Pelican Narrows, Rare-earth element

VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Lancaster Resources Inc. (CSE:LCR | OTCQB:LANRF | FRA:6UF0) (“Lancaster” or the “Company”), a North American critical minerals exploration company, is excited to announce the acquisition of the Piney Lake Gold Property.

Key Points: 
  • VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Lancaster Resources Inc. (CSE:LCR | OTCQB:LANRF | FRA:6UF0) (“Lancaster” or the “Company”), a North American critical minerals exploration company, is excited to announce the acquisition of the Piney Lake Gold Property.
  • The Piney Lake Gold Property, covering an area of 2,267.8 hectares, is nestled approximately 65 kilometres east of La Ronge Provincial Park and a mere 2.5 kilometres east of North Arrow Minerals' Pikoo property.
  • Access to the Piney Lake property is facilitated by provincial highways, placing it about 18 kilometres to the southwest of Pelican Narrows via Highway 135 and similarly accessible to Deschambault Lake via Highway 911.
  • "The acquisition of the Piney Lake Gold Property is an exciting project to add to our growing exploration portfolio,” says Penny White, President and Chief Executive Officer of Lancaster.

The Foundation for Women's Cancer Named "Partner-of-Choice" by The Institute for Surgical Excellence Receiving $155,555 to Drive Change in Women's Cancer

Retrieved on: 
Thursday, April 18, 2024
Education, SGO, Society, Cancer, Cure, Learning, Social media, Machine learning, Surgeon, Gynecologic Oncology (journal), Research, Artificial intelligence, Ginger, Celebration, Patient, Society of Gynecologic Oncology, Physician, Movement, Oncology nursing, FWC, Student, FACOG, Knowledge

CHICAGO, April 18, 2024 /PRNewswire-PRWeb/ -- The Foundation for Women's Cancer (FWC), the official foundation of the Society of Gynecologic Oncology (SGO), launched its signature annual fundraising campaign, Move4Her, last month in San Diego in conjunction with the Institute for Surgical Excellence (ISE) Celebration of Champions Day (March 14), FWC Patient & Advocate Education Forum (March 15), and SGO Annual Meeting on Women's Cancer (March 16-18).

Key Points: 
  • "It was spectacular to bring so many people together for a common cause, to share knowledge and build community.
  • The resulting donation from the ISE to the FWC will help meet critical needs in education, awareness, and grants to further research in women's cancer."
  • "It was spectacular to bring so many people together for a common cause, to share knowledge and build community.
  • "There are so many exciting medical breakthroughs happening that will improve the lives of people faced with a cancer diagnosis.

SONORO GOLD CLOSES OVER-SUBSCRIBED $1 MILLION NON-BROKERED PRIVATE PLACEMENT

Retrieved on: 
Tuesday, April 2, 2024
TSX Venture Exchange, Offering, Minority, SGO, Multilateral, Policy

VANCOUVER, Canada, April 02, 2024 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce that it has closed the final tranche of its over-subscribed non-brokered private placement (the “Offering”) for additional gross proceeds of C$616,079.

Key Points: 
  • VANCOUVER, Canada, April 02, 2024 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce that it has closed the final tranche of its over-subscribed non-brokered private placement (the “Offering”) for additional gross proceeds of C$616,079.
  • Each Unit consists of one Sonoro common share and one common share purchase warrant.
  • Each warrant entitles the holder thereof to purchase one additional Sonoro common share for a period of three years from the closing of the private placement at an exercise price of C$0.07 per share.
  • The net proceeds from the Offering will be used to fund the ongoing development of the Company’s Cerro Caliche gold project in Sonora, Mexico.

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer

Retrieved on: 
Monday, March 18, 2024
Ovarian cancer, Mutation, Serum, Patient, Pharming, SGO, Gynecologic Oncology (journal), Platinum, Pharmaceutical industry

Rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets the TP53 Y220C mutation in solid tumors.

Key Points: 
  • Rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets the TP53 Y220C mutation in solid tumors.
  • These data were featured today in a late-breaking oral presentation at the 2024 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer being held March 16-18, 2024 in San Diego, CA.
  • “In this Phase 1 study, we observed promising efficacy of rezatapopt in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation.
  • Our registrational, tumor-agnostic PYNNACLE Phase 2 trial, which includes an ovarian cancer cohort, remains on track to initiate in the first quarter of this year.

SONORO GOLD APPOINTS KATHARINE REGAN TO BOARD OF DIRECTORS

Retrieved on: 
Tuesday, March 12, 2024
GPC, SGO, Annual general meeting, Gold, Corporate development, Corporation, Management

VANCOUVER, Canada, March 12, 2024 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce the appointment of Katharine Regan to the Company’s Board of Directors, in addition to her position of Vice President of Corporate Development and Corporate Secretary.

Key Points: 
  • VANCOUVER, Canada, March 12, 2024 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce the appointment of Katharine Regan to the Company’s Board of Directors, in addition to her position of Vice President of Corporate Development and Corporate Secretary.
  • Ms. Regan will stand for election by the Shareholders of the Company at the next Annual General Meeting.
  • John Darch, Chairman of the Board of Directors, commented “We are very pleased to welcome Katharine Regan to the Board.
  • She was appointed Corporate Secretary of Sonoro Gold in 2019 and Vice-President of Corporate Development in 2022.

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

Retrieved on: 
Wednesday, April 3, 2024
Pharmaceutical, Health, Oncology, Clinical Trials, MSD, DXD, CDH6, Survival, Glomus tumor, Patient, Merck & Co., SGO, MD, Society, Senior, MRK, Safety, Gynecologic Oncology (journal), Recurrence, ADC, Daiichi Sankyo, Annual general meeting, Pharmaceutical industry

The phase 2 portion of the trial will be conducted to identify the dose of raludotatug deruxtecan to be used in the phase 3 part of the trial, which will evaluate raludotatug deruxtecan versus investigator’s choice of chemotherapy.

Key Points: 
  • The phase 2 portion of the trial will be conducted to identify the dose of raludotatug deruxtecan to be used in the phase 3 part of the trial, which will evaluate raludotatug deruxtecan versus investigator’s choice of chemotherapy.
  • Raludotatug deruxtecan is an investigational specifically engineered potential first-in-class CDH6 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed with Merck.
  • “Raludotatug deruxtecan has shown promising activity in a phase 1 trial of patients with advanced ovarian cancer,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development, Daiichi Sankyo.
  • “We look forward to working with our colleagues at Daiichi Sankyo to further evaluate the potential of raludotatug deruxtecan to provide a new treatment option for patients with platinum-resistant ovarian cancer.”

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

Retrieved on: 
Monday, March 18, 2024
Mental Health, Research, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Diagnosis, Ovarian cancer, Friends, Uncertainty, Employment, Disease, Risk, Patient, Mental health, Cancer, Anxiety, SGO, Quality of life, Life, Society, Woman, Verastem Oncology, Gynecologic Oncology (journal), Recurrence, Family, FDA, Massage chair, Work

The results reveal a significant negative impact of LGSOC on respondents’ mental and physical health, worry and anxiety about cancer recurrence, side effects from treatment, and disruption to aspects of daily life such as relationships, family, work, and finances.

Key Points: 
  • The results reveal a significant negative impact of LGSOC on respondents’ mental and physical health, worry and anxiety about cancer recurrence, side effects from treatment, and disruption to aspects of daily life such as relationships, family, work, and finances.
  • Other impacts that were noted by survey respondents include, negative effects on their mental health (73%), physical health (80%), overall quality of life (73%), finances (54%) and primary relationships (46%).
  • What is often not understood is that standard-of-care chemotherapies are minimally effective and often accompanied by severe side effects.
  • 68% of respondents reported a negative impact on their jobs or careers, with 52% missing work to manage their cancer and 23% having to cut back on necessities to afford treatment.

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Strategic management, Diagnosis, Initiation, Research and development, Conference, Immunotherapy, Part, FAK, New Drug Application, Patient, Cancer, RAMP, Accelerated approval (FDA), NDA, Table, SGO, BRAF, Society, IND, Abstract, Bank statement, AACR, Pancreatic cancer, Investment, Verastem Oncology, MEK, Therapy, Safety, GAAP, Gynecologic Oncology (journal), Food, FDA, Annual general meeting, Pharmaceutical industry

Verastem Oncology ended the fourth quarter of 2023 with cash, cash equivalents and investments of $137.1 million.

Key Points: 
  • Verastem Oncology ended the fourth quarter of 2023 with cash, cash equivalents and investments of $137.1 million.
  • Research & development expenses for the 2023 Quarter were $22.5 million, compared to $10.7 million for the 2022 Quarter.
  • Selling, general & administrative expenses for the 2023 Quarter were $8.6 million, compared to $6.1 million for the 2022 Quarter.
  • These non-GAAP financial measures exclude certain amounts or expenses from the corresponding financial measures determined in accordance with GAAP.

Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers

Retrieved on: 
Tuesday, March 12, 2024
Research, Women, Genetics, Clinical Trials, Biotechnology, Health, Consumer, Science, Oncology, Ovarian cancer, Patient, DNA, SGO, MD, Abstract, NTRA, Breast cancer, MRD, Gynecologic Oncology (journal), Medicare, Society of Gynecologic Oncology, Birth control

A total of seven abstracts will be presented, including two oral presentations and five poster presentations.

Key Points: 
  • A total of seven abstracts will be presented, including two oral presentations and five poster presentations.
  • The presentations will feature new data highlighting Signatera’s predictive and prognostic utility in ovarian cancer and other gynecologic malignancies.
  • “On the heels of receiving Medicare coverage for Signatera in ovarian cancer and for breast cancer in the neoadjuvant setting, we are thrilled to share new Signatera and Empower data with the gynecologic oncology community,” said Adam ElNaggar, MD, medical director of oncology at Natera.
  • “We believe this momentum is indicative of the growing clinical value our tests provide for patients across the continuum of gynecologic cancer care, and demonstrate our continued leadership in MRD.”
    Below is the full list of Signatera and Empower data presentations at the SGO Annual Meeting.

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

Retrieved on: 
Monday, March 11, 2024
Biotechnology, General Health, Health, Pharmaceutical, Oncology, FAK, Patient, Research, RAMP, Cancer, SGO, Society, Woman, Clinical trial, Verastem Oncology, DRS, MEK, Gynecologic Oncology (journal), Consultant, Annual general meeting, Pharmaceutical industry

Verastem will have an exhibition booth (#420) at the meeting to provide an overview of its ongoing cancer research.

Key Points: 
  • Verastem will have an exhibition booth (#420) at the meeting to provide an overview of its ongoing cancer research.
  • “In addition, the plenary oral presentation highlighting preclinical efficacy of avutometinib in combination with a FAK inhibitor reinforces the potential of this combination in low-grade serous ovarian cancer regardless of KRAS status.
  • Banerjee and Grisham are paid consultants for Verastem Oncology.
  • The multinational survey is supported by Verastem Oncology.